Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

被引：0
|
作者：
Naismith, R. T. [1 ]
Cohen, J. A. [2 ]
Bar-Or, A. [3 ,4 ]
Comi, G. [5 ]
Selmaj, K. W. [6 ,7 ]
Hartung, H. [8 ]
Sheffield, J. K. [9 ]
Minton, N. [9 ]
Gleichmann, M. [9 ]
Liu, H. [9 ]
Riolo, J. [9 ]
Silva, D. [9 ]
Cree, B. A. [10 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH 44106 USA
[3] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurol, Milan, Italy
[6] Ctr Neurol, Lodz, Poland
[7] Univ Warmia & Mazury, Dept Neurol, Coll Med, Olsztyn, Poland
[8] Heinrich Heine Univ, Fac Med, Dept Neurol, Dusseldorf, Germany
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P080
引用
收藏
页码：53 / 54
页数：2
相关论文
共 50 条
  • [31] Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Rubin, David T.
    Cree, Bruce A. C.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Cohen, Jeffrey A.
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S680 - S680
  • [32] Rate of Confirmed Macular Oedema With Ozanimod in Patients With Relapsing Multiple Sclerosis: Results From the Ozanimod RMS Clinical Development Program
    Gross, S. A.
    Minton, N.
    Sheffield, J. K.
    Henry, A.
    Calkwood, J.
    Selmaj, K. W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 919 - 920
  • [33] Effect of ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis and comparison with healthy volunteers
    Harris, S.
    Maddux, R.
    Hoffmueller, U.
    Raschke, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 567 - 567
  • [34] Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
    Rubin, David T.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Afsari, Sonia
    Petersen, Ann Katrin
    Sheffield, James
    Li, Hongjuan
    Silva, Diego
    Lublin, Fred D.
    Cree, Bruce
    Cohen, Jeffrey
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S396 - S396
  • [35] Baseline Whole Brain Volume and Disability Progression in Ozanimod-Treated Patients With Relapsing Multiple Sclerosis
    Filippi, M.
    Cohen, J. A.
    Arnold, D. L.
    Hartung, H. P.
    Cheng, C. Y.
    Pachai, C.
    Riolo, J. V.
    Silva, D.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 183 - 183
  • [36] Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
    Hauser, Stephen L.
    Kappos, Ludwig
    Montalban, Xavier
    Craveiro, Licinio
    Chognot, Cathy
    Hughes, Richard
    Koendgen, Harold
    Pasquarelli, Noemi
    Pradhan, Ashish
    Prajapati, Kalpesh
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 97 (16) : E1546 - E1559
  • [37] Pharmacovigilance program for ozanimod, a recently approved treatment for relapsing forms of multiple sclerosis
    Afsari, S.
    Dietz, D.
    Minton, N.
    Kou, D.
    Lee, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 234 - 235
  • [38] Efficacy of Ozanimod in Disease-Modifying Treatment Naive vs Experienced Patients With Relapsing Multiple Sclerosis
    Centonze, D.
    Hartung, H.
    Montalban, X.
    Cheng, C.
    Riolo, J.
    Meuth, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 203 - 203
  • [39] Gray Matter Volume Loss Is Increased in Younger Patients with Relapsing Multiple Sclerosis but Minimized by Ozanimod: Experience From the Ozanimod Phase 3 Program
    Schippling, Sven
    Cree, Bruce A. C.
    Montalban, Xavier
    Arnold, Douglas L.
    Kappos, Ludwig
    Comi, Giancarlo
    Bodhinathan, Karthik
    Chen, Yu
    Sheffield, James K.
    Silva, Diego
    NEUROLOGY, 2019, 92 (15)
  • [40] Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
    Hauser, Stephen L.
    Kappos, Ludwig
    Montalban, Xavier
    Craveiro, Licinio
    Hughes, Richard
    Prajapati, Kalpesh
    Koendgen, Harold
    Pradhan, Ashish
    Wolinsky, Jerry S.
    NEUROLOGY, 2020, 94 (15)
12345